Spruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B

Reuters01-28

<a href="https://laohu8.com/S/SPRB">Spruce Biosciences</a> Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Inc. has announced upcoming presentations of clinical data regarding its investigational enzyme replacement therapy, tralesinidase alfa (TA-ERT), for the treatment of Sanfilippo syndrome type B (MPS IIIB). The data, to be presented at the 22nd Annual WORLDSymposium™ from February 2-6, 2026 in San Diego, will include findings on the long-term administration of TA-ERT, showing its impact on reducing heparan sulfate levels and stabilizing cognitive function and cortical gray matter volume in patients. Additionally, a separate presentation will detail divergent neurocognitive outcomes in two siblings with MPS IIIB, one treated with TA-ERT and the other receiving supportive care. The results have not yet been presented and are scheduled for February 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260128573673) on January 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606719752?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-28 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606719752","market":"nz","top_or_hot":-1,"title":"Spruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SPRB\">Spruce Biosciences</a> Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spruce Biosciences Inc. has announced upcoming presentations of clinical data regarding its investigational enzyme replacement therapy, tralesinidase alfa (TA-ERT), for the treatment of Sanfilippo syndrome type B (MPS IIIB). The data, to be presented at the 22nd Annual WORLDSymposium™ from February 2-6, 2026 in San Diego, will include findings on the long-term administration of TA-ERT, showing its impact on reducing heparan sulfate levels and stabilizing cognitive function and cortical gray matter volume in patients. Additionally, a separate presentation will detail divergent neurocognitive outcomes in two siblings with MPS IIIB, one treated with TA-ERT and the other receiving supportive care. The results have not yet been presented and are scheduled for February 5, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260128573673) on January 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-28 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SPRB\">Spruce Biosciences</a> Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spruce Biosciences Inc. has announced upcoming presentations of clinical data regarding its investigational enzyme replacement therapy, tralesinidase alfa (TA-ERT), for the treatment of Sanfilippo syndrome type B (MPS IIIB). The data, to be presented at the 22nd Annual WORLDSymposium™ from February 2-6, 2026 in San Diego, will include findings on the long-term administration of TA-ERT, showing its impact on reducing heparan sulfate levels and stabilizing cognitive function and cortical gray matter volume in patients. Additionally, a separate presentation will detail divergent neurocognitive outcomes in two siblings with MPS IIIB, one treated with TA-ERT and the other receiving supportive care. The results have not yet been presented and are scheduled for February 5, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260128573673) on January 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SPRB","symbol_name":"Spruce Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL773dGB:1","article_id":"2606719752","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606719752","pubTimestamp":1769605262,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spruce Biosciences Inc. has announced upcoming presentations of clinical data regarding its investigational enzyme replacement therapy, tralesinidase alfa , for the treatment of Sanfilippo syndrome type B . The data, to be presented at the 22nd Annual WORLDSymposium from February 2-6, 2026 in San Diego, will include findings on the long-term administration of TA-ERT, showing its impact on reducing heparan sulfate levels and stabilizing cognitive function and cortical gray matter volume in patients. Additionally, a separate presentation will detail divergent neurocognitive outcomes in two siblings with MPS IIIB, one treated with TA-ERT and the other receiving supportive care. The results have not yet been presented and are scheduled for February 5, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sho","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SPRB":"Spruce Biosciences, Inc.","BK4139":"生物科技"},"translate_title":"Spruce Biosciences报告曲莱西尼酶α治疗B型Sanfilippo综合征的积极长期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRB":0.9},"content_text":"Spruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B\n    \n\n        Spruce Biosciences Inc. has announced upcoming presentations of clinical data regarding its investigational enzyme replacement therapy, tralesinidase alfa (TA-ERT), for the treatment of Sanfilippo syndrome type B (MPS IIIB). The data, to be presented at the 22nd Annual WORLDSymposium™ from February 2-6, 2026 in San Diego, will include findings on the long-term administration of TA-ERT, showing its impact on reducing heparan sulfate levels and stabilizing cognitive function and cortical gray matter volume in patients. Additionally, a separate presentation will detail divergent neurocognitive outcomes in two siblings with MPS IIIB, one treated with TA-ERT and the other receiving supportive care. The results have not yet been presented and are scheduled for February 5, 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260128573673) on January 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606719752","isCrawlerRequest":true}